Epizyme Inc. (EPZM)

10.85
0.01 0.09
NASDAQ : Health Technology
Prev Close 10.84
Open 10.80
Day Low/High 10.71 / 10.92
52 Wk Low/High 5.14 / 16.59
Volume 236.99K
Avg Volume 632.10K
Exchange NASDAQ
Shares Outstanding 91.04M
Market Cap 941.32M
EPS -1.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Epizyme Presents Data From Tazemetostat Clinical Pharmacology Studies At American Association For Cancer Research Annual Meeting 2016

Epizyme Presents Data From Tazemetostat Clinical Pharmacology Studies At American Association For Cancer Research Annual Meeting 2016

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today presented data from clinical studies that investigated the effect of food...

Epizyme (EPZM) Strong On High Relative Volume Today

Epizyme (EPZM) Strong On High Relative Volume Today

Trade-Ideas LLC identified Epizyme (EPZM) as a strong on high relative volume candidate

Epizyme To Present New Data In Support Of Tazemetostat Clinical Development Program

Epizyme To Present New Data In Support Of Tazemetostat Clinical Development Program

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today announced that data from five accepted abstracts of tazemetostat (EPZ-6438), its...

Epizyme Announces 2015 Financial Results And Financial Guidance

Epizyme Announces 2015 Financial Results And Financial Guidance

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for patients with cancer, today highlighted certain 2015 and recent accomplishments and reported financial results...

Epizyme Unveils Corporate Strategy To Guide Efforts Over Next Five Years

Epizyme Unveils Corporate Strategy To Guide Efforts Over Next Five Years

Epizyme, Inc., (NASDAQ:EPZM) a clinical stage biopharmaceutical company creating novel epigenetic therapies for patients with cancer, today announced its corporate vision and strategy through 2020.

5 Stocks Set to Soar on Bullish Earnings

5 Stocks Set to Soar on Bullish Earnings

These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.

Epizyme To Report 2015 Financial Results And Provide Business Updates On March 9, 2016

Epizyme To Report 2015 Financial Results And Provide Business Updates On March 9, 2016

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced today it will host a conference call on Wednesday, March 9, 2016 at 8:00 a.

Short Interest Increases 24.6% For EPZM

Short Interest Increases 24.6% For EPZM

The most recent short interest data has been released by the NASDAQ for the 02/12/2016 settlement date, which shows a 900,374 share increase in total short interest for Epizyme Inc. , to 4,567,956, an increase of 24.55% since 01/29/2016.

Epizyme Is Now Oversold (EPZM)

Epizyme Is Now Oversold (EPZM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Epizyme Execs Pocket Cheap Stock Options, Tone Deaf to Shareholder Pain

Epizyme Execs Pocket Cheap Stock Options, Tone Deaf to Shareholder Pain

With new stock option grants this week, Epizyme executives are sending an ugly message to aggrieved shareholders: We don't mind profiting from your pain.

Epizyme Announces Tazemetostat Granted Orphan Drug Designation For Malignant Rhabdoid Tumors By U.S. FDA

Epizyme Announces Tazemetostat Granted Orphan Drug Designation For Malignant Rhabdoid Tumors By U.S. FDA

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced today that the United States Food and Drug Administration (FDA) has...

Epizyme To Present At Upcoming Investor Conferences

Epizyme To Present At Upcoming Investor Conferences

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that the Company will participate in four investor conferences in February:...

Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?

Biotech String: Assessing the January Damage, Gilead's Bottoming P/E, Sarepta Panel Date?

Biotech news and observations to start the week.

Short Interest In Epizyme Moves 31.7% Lower

Short Interest In Epizyme Moves 31.7% Lower

The most recent short interest data has been released by the NASDAQ for the 01/15/2016 settlement date, which shows a 1,700,489 share decrease in total short interest for Epizyme Inc. , to 3,662,929, a decrease of 31.71% since 12/31/2015.

First Week of EPZM March 18th Options Trading

First Week of EPZM March 18th Options Trading

Investors in Epizyme Inc. saw new options begin trading this week, for the March 18th expiration.

Epizyme Announces Closing Of Public Offering Of Common Stock

Epizyme Announces Closing Of Public Offering Of Common Stock

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced the closing of its public offering of 15,333,334 shares of its common...

Oversold Conditions For Epizyme (EPZM)

Oversold Conditions For Epizyme (EPZM)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Epizyme Announces Pricing Of Public Offering Of Common Stock

Epizyme Announces Pricing Of Public Offering Of Common Stock

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced the pricing of its public offering of 13,333,334 shares of its common stock...

Epizyme Announces Proposed Public Offering Of Common Stock

Epizyme Announces Proposed Public Offering Of Common Stock

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, today announced that it intends to offer and sell up to $120,000,000 of shares of its...

Epizyme Announces First Patient Dosed In Global Clinical Program Evaluating Tazemetostat In Genetically Defined Solid Tumors

Epizyme Announces First Patient Dosed In Global Clinical Program Evaluating Tazemetostat In Genetically Defined Solid Tumors

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that the first patient has been dosed in the phase 2 study of tazemetostat in...

Short Interest Jumps 11.4% For EPZM

Short Interest Jumps 11.4% For EPZM

The most recent short interest data has been released by the NASDAQ for the 12/15/2015 settlement date, which shows a 619,146 share increase in total short interest for Epizyme Inc. , to 6,031,075, an increase of 11.44% since 11/30/2015.

Epizyme Announces FDA Acceptance Of Investigational New Drug Application For Tazemetostat In Diffuse Large B-cell Lymphoma

Epizyme Announces FDA Acceptance Of Investigational New Drug Application For Tazemetostat In Diffuse Large B-cell Lymphoma

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today announced the U.

Insider Trading Alert - ABAX, EPZM And ERI Traded By Insiders

Insider Trading Alert - ABAX, EPZM And ERI Traded By Insiders

Stocks with insider trader activity include ABAX, EPZM and ERI

Epizyme Presents Updated Data From Ongoing Phase 1 Study Of Tazemetostat Showing Objective, Durable Responses In Relapsed Or Refractory Non-Hodgkin Lymphoma

Epizyme Presents Updated Data From Ongoing Phase 1 Study Of Tazemetostat Showing Objective, Durable Responses In Relapsed Or Refractory Non-Hodgkin Lymphoma

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, reported updated results from the ongoing phase 1 trial of tazemetostat (EPZ-6438),...

Epizyme, Inc. To Present At Piper Jaffray Conference On December 1, 2015

Epizyme, Inc. To Present At Piper Jaffray Conference On December 1, 2015

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, will participate in the Piper Jaffray 27 th Annual Healthcare Conference at the Lotte...

Epizyme Announces Third Quarter 2015 Financial Results And Provides Corporate Update

Epizyme Announces Third Quarter 2015 Financial Results And Provides Corporate Update

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, today reported business highlights and operating and financial results for the third quarter...

Epizyme Announces Presentations At 57th American Society Of Hematology Annual Meeting

Epizyme Announces Presentations At 57th American Society Of Hematology Annual Meeting

Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, announced today that data from the ongoing phase 1 study of tazemetostat (EPZ-6438) will be...

Epizyme To Present New Scientific Data On The Role Of HMT Inhibitors In Cancer

Epizyme To Present New Scientific Data On The Role Of HMT Inhibitors In Cancer

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for cancer patients, will present data from 11 accepted abstracts on the role of histone methyltransferase (HMT)...

Epizyme To Report Third Quarter 2015 Financial Results And Provide Corporate Update On November 9, 2015

Epizyme To Report Third Quarter 2015 Financial Results And Provide Corporate Update On November 9, 2015

Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, announced today it will host a conference call and live audio webcast on Monday, November...

Interesting EPZM Put And Call Options For May 2016

Interesting EPZM Put And Call Options For May 2016

Investors in Epizyme Inc. saw new options begin trading this week, for the May 2016 expiration.

TheStreet Quant Rating: D (Sell)